Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Maeve Aine Lowery, Ghassan K. Abou-Alfa, Howard A. Burris, Filip Janku, Rachna T. Shroff, James M. Cleary, Nilofer Saba Azad, Lipika Goyal, Elizabeth A. Maher, Lia Gore, Antoine Hollebecque, Muralidhar Beeram, Jonathan C. Trent, Liewen Jiang, Yuko Ishii, Julia Auer, Camelia Gliser, Samuel V. Agresta, Shuchi Sumant Pandya, Andrew X. Zhu
Institutions: Memorial Sloan Kettering Cancer Center, Sarah Cannon, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Harvard University, Massachusetts General Hospital, The University of Texas Southwestern Medical Center, University of Colorado Cancer Center, Institut Gustave Roussy, South Texas Accelerated Research Therapeutics, Sylvester Comprehensive Cancer Center, Agios Pharmaceuticals (United States)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2886807331